Nutraceutical Capsules LL1 and Silymarin Supplementation Act on Mood and Sleep Quality Perception by Microbiota-Gut-Brain Axis: A Pilot Clinical Study

• Published in: Nutrients Vol. 16; no. 18; p. 3049
• Main Authors: Santamarina, Aline Boveto, Nehmi Filho, Victor, Freitas, Jéssica Alves de, Franco, Lucas Augusto Moysés, Fonseca, Joyce Vanessa, Martins, Roberta Cristina, Turri, José Antônio Orellana, Silva, Bruna Fernanda Rio Branco da, Gusmão, Arianne Fagotti, Olivieri, Eloísa Helena Ribeiro, Otoch, José Pinhata, Pessoa, Ana Flávia Marçal
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10-09-2024; MDPI
• Subjects: Adult; Affect - drug effects; Anxiety; Body mass index; Brain; Brain research; Brain-Gut Axis - drug effects; Capsules; Chemokines; Cholesterol; Clinical trials; Cognition disorders; Cognitive ability; Cytokines; Cytokines - blood; Cytokines - metabolism; Dietary minerals; Dietary Supplements; dysbiosis; Emotional disorders; Esters; Ethics; Exercise; Fatty acids; Feces - microbiology; Female; Functional foods; Functional foods & nutraceuticals; Gastrointestinal Microbiome - drug effects; gut-brain axis; Humans; Inflammation; Male; Mental health; Microbiota; Microbiota (Symbiotic organisms); Middle Aged; Mood disorders; Overweight; Pilot Projects; Prebiotics; Prebiotics - administration & dosage; Quality of Life; Questionnaires; RNA, Ribosomal, 16S; Sample size; Selenium; Silymarin - pharmacology; Sleep; Sleep disorders; Sleep Quality; Software; Taxonomy; Brazil; United States > US; microbiota; sleep; prebiotics; inflammation; dysbiosis; gut-brain axis
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu16183049

Stress, unhealthy lifestyle, and sleep disturbance worsen cognitive function in mood disorders, prompting a rise in the development of integrative health approaches. The recent investigations in the gut-brain axis field highlight the strong interplay among microbiota, inflammation, and mental health. Thus, this study aimed to investigate a new nutraceutical formulation comprising prebiotics, minerals, and silymarin's impact on microbiota, inflammation, mood, and sleep quality. The study evaluated the LL1 + silymarin capsule supplementation over 180 days in overweight adults. We analyzed the fecal gut microbiota using partial 16S rRNA sequences, measured cytokine expression via CBA, collected anthropometric data, quality of life, and sleep questionnaire responses, and obtained plasma samples for metabolic and hormonal analysis at baseline (T0) and 180 days (T180) post-supplementation. Our findings revealed significant reshaping in gut microbiota composition at the phylum, genus, and species levels, especially in the butyrate-producer bacteria post-supplementation. These changes in gut microbiota were linked to enhancements in sleep quality, mood perception, cytokine expression, and anthropometric measures which microbiota-derived short-chain fatty acids might enhance. The supplementation tested in this study seems to be able to improve microbiota composition, reflecting anthropometrics and inflammation, as well as sleep quality and mood improvement.